Impact of Initial Influenza Exposure on Immunity in Infants
ID: 359939Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359939
Timeline
    Description

    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Impact of Initial Influenza Exposure on Immunity in Infants," aimed at advancing research on how influenza infections and vaccinations affect infant and childhood immunity. The initiative seeks to establish and characterize longitudinal cohorts of infants and mother-infant dyads to investigate the influence of initial exposure to influenza antigens on immune responses to subsequent infections and vaccinations. This research is critical for developing durable and broadly protective influenza vaccines. The estimated total program funding is $10 million, with three awards expected, and interested applicants can reach out to Dr. Michelle M. Arnold at michelle.arnold@nih.gov or by phone at 301-761-7324. Key deadlines include an estimated synopsis close date of February 11, 2026, and an estimated award date of December 1, 2026.

    Point(s) of Contact
    Michelle M. Arnold, Ph.D. National Institute of Allergy and Infectious Diseases (NIAID)
    (301) 761-7324
    michelle.arnold@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Immune System Development and Ontogeny" under the R01 Clinical Trial Optional grant program. This initiative aims to investigate the mechanisms of early immune development in children, particularly focusing on those with in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART), and includes research on maternal and paternal immune statuses, immune cell development, and environmental influences. The program is significant for advancing laboratory research and clinical trials that enhance understanding of immune maturation in neonates and children. Eligible applicants can receive up to $400,000 per year for a maximum project duration of four years, with applications opening on April 7, 2025, and closing on January 8, 2029. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Influenza Transmission Research Consortium (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Influenza Transmission Research Consortium (P01 Clinical Trial Optional)" aimed at advancing research on the mechanisms of human-to-human transmission of seasonal influenza virus. This initiative seeks to establish a network of Influenza Transmission Research Centers that will foster collaborative, multidisciplinary teams to investigate the dynamics and drivers of influenza transmission, ultimately developing novel resources for the field of respiratory virus transmission. With an estimated total program funding of $8 million and the expectation of awarding three grants, interested applicants are encouraged to begin forming collaborations and preparing their proposals ahead of the anticipated application solicitation, which is expected to open in September 2025. For further inquiries, potential applicants can contact Brooke Bozick, Ph.D., at brooke.bozick@mail.nih.gov or by phone at 301-761-6710.
    Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" (FO No. PAR-24-112) aimed at enhancing research on innate immune memory. This initiative seeks to support studies that identify biomarkers of trained immunity, elucidate underlying molecular mechanisms, and assess the implications for immune system function, particularly in relation to vaccines, infections, and autoimmune or allergic diseases. The funding is crucial for advancing immunological research with significant public health implications, and applications are due by June 5, 2024, and October 5, 2024. Interested applicants can find more information and submit their proposals via Grants.gov, and for inquiries, they may contact NIH Grants Information at grantsinfo@nih.gov.
    Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" through the R21 grant mechanism, aimed at advancing research into innate immune memory, known as trained immunity. This initiative seeks to enhance understanding of the mechanisms, biomarkers, and functional implications of trained immunity, particularly in relation to immune system development, vaccine efficacy, and various diseases, while explicitly prohibiting clinical trials. The grant provides a maximum funding amount of $275,000, with applications accepted starting May 16, 2024, and a closing date of January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Coccidioidomycosis Collaborative Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Coccidioidomycosis Collaborative Research Centers" aimed at advancing research to develop a vaccine for coccidioidomycosis, commonly known as Valley fever. This initiative seeks to support multi-disciplinary research centers that will address critical gaps in basic research, develop necessary tools and resources, and ultimately create a preventative vaccine for this serious fungal infection endemic to various regions in the United States. The grant is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, community-based organizations, and foreign institutions, with no cost-sharing or matching requirement. Interested parties can reach out to Dr. Dona Love at dona.love@nih.gov or by phone at 301-761-7788 for further information. The estimated synopsis post date is January 5, 2026, with a closing date for applications on March 6, 2026, and an anticipated award date of December 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for HIV Pediatric, Adolescent and Maternal Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on high-priority HIV studies targeting infants, children, adolescents, young adults, and maternal populations. This initiative aims to establish an HIV clinical trials network dedicated to these demographics, fostering innovative and collaborative clinical trials to address significant research areas in HIV and related health issues. The estimated total program funding is $30 million, with two awards anticipated, and potential applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on November 21, 2025. For further inquiries, interested parties may contact Dr. Sonia Lee at Sonia.lee@nih.gov or by phone at 301-594-4783.
    Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research." This initiative aims to support the secondary use of archived data and biospecimen collections to enhance research in maternal, pediatric, and adolescent HIV, encouraging the integration of innovative data science methods and interdisciplinary approaches. With an estimated total program funding of $1,000,000 and the expectation of awarding two grants, interested small businesses can reach out to Samantha Calabrese at samantha.calabrese@nih.gov or call 301-827-7568 for more information. Key deadlines include an estimated synopsis post date of October 1, 2025, and a closing date of January 2, 2026, with project start and award dates anticipated for July 1, 2026.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)" aimed at expanding knowledge of disorders that are currently or may become part of statewide newborn screening programs. This initiative seeks to gather comprehensive data on the natural history of these conditions to facilitate appropriate interventions for affected infants, improve diagnostic accuracy, and support the development of targeted treatments. The funding will assist in identifying biological mechanisms, understanding genetic diversity, and establishing data collection systems for longitudinal studies, emphasizing the importance of research in newborn screening. Interested applicants, including various educational and community organizations, can submit proposals with a maximum project period of five years, with the funding cycle opening on January 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-227.html.